Tyra Biosciences Says FDA Granted Rare Pediatric Disease Designation To TYRA-300, An Oral FGFR3 Selective Inhibitor, For Treatment Of Achondroplasia, The Most Common Form Of Dwarfism With Limited Therapeutic Options
Author: Benzinga Newsdesk | February 01, 2024 06:33pm